(RZLT) – StreetInsider.com Reports
-
Jones Trading Starts Rezolute (RZLT) at Buy, 'an under-appreciated player in the rare disease space'
-
Maxim Group Starts Rezolute (RZLT) at Buy
-
Rezolute (RZLT) Reports Validation of the Potential Use of RZ358
-
Rezolute (RZLT) PT Raised to $9 at Canaccord Genuity
-
Rezolute Inc. (RZLT) Appoints Daron Evans as CFO
-
Rezolute Inc. (RZLT) Files $200M Mixed Shelf
-
Rezolute Inc. (RZLT) Files $200M Mixed Shelf
-
Rezolute, Inc. (RZLT) Tops Q1 EPS by 3c
-
Rezolute (RZLT) PT Lowered to $7 at JMP Securities
-
Rezolute Inc. (RZLT) Receives PRIME Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
-
Rezolute (RZLT) Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
-
Rezolute (RZLT) PT Lowered to $4 at Jefferies
-
Rezolute (RZLT) PT Raised to $7 at Cantor Fitzgerald
-
Rezolute (RZLT) PT Raised to $17 at Canaccord Genuity
-
Rezolute (RZLT) PT Lowered to $14 at H.C. Wainwright
-
Rezolute (RZLT) PT Lowered to $17 at H.C. Wainwright
-
Rezolute Inc. (RZLT) Announces 3.24M Share Offering by Selling Stockholders
-
UPDATE: Jefferies Starts Rezolute (RZLT) at Buy
-
Canaccord Genuity Assumes Rezolute (RZLT) at Buy
-
Rezolute Inc. (RZLT) Announces 10.95M Share Offering by Selling Stockholders
-
Rezolute Inc. (RZLT) Announces 10.95M Share Offering by Selling Stockholders
-
UPDATE: Cantor Fitzgerald Starts Rezolute (RZLT) at Overweight
-
Rezolute Inc. (RZLT) Appoints Brian Roberts as Chief Medical Officer
-
Rezolute (RZLT) PT Lowered to $23 at Oppenheimer
-
Rezolute (RZLT) PT Lowered to $8 at JMP Securities
-
Rezolute Inc. (RZLT) Reports Positive Data from Phase 2b (RIZE) Study of RZ358
-
Rezolute Inc. (RZLT) Prices 18M Share Offering at $3.80/sh
-
Rezolute (RZLT) PT Raised to $25 at Roth Capital
-
Pre-Open Stock Movers 03/23: (RZLT) (HYMC) (GME) Higher; (GAN) (POSH) (WOR) Lower
-
Rezolute Inc. (RZLT) Climbs 23% Following Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
-
Rezolute Inc. (RZLT) Reports Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
-
Rezolute Inc. (RZLT) Reports Positive Study Results for RZ402
-
Rezolute (RZLT) PT Lowered to $17 at Canaccord Genuity, Keeps 'Buy'
-
Rezolute (RZLT) PT Lowered to $18 at JMP Securities
-
Pre-Open Stock Movers 10/13: (WTRH) (KOSS) (RVNC) Higher; (RGLS) (ARDX) (STIM) Lower (more...)
-
Rezolute Inc. (RZLT) Prices 6.03M Share Offering at $6.50/sh and Concurrent Registered Offering of 769k Shares at $6.50/sh
-
After-Hours Stock Movers 10/12: (JSPR) (VST) (QCOM) Higher; (RGLS) (STIM) (RZLT) Lower (more...)
-
Rezolute Inc. (RZLT) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
-
Rezolute (RZLT) Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE
-
Roth Capital Starts Rezolute (RZLT) at Buy
-
Rezolute Inc. (RZLT) halted again on volatility, up 114%
-
Rezolute Inc. (RZLT) Surges, Halted on New Bullish Rating
-
UPDATE: Oppenheimer Starts Rezolute (RZLT) at Outperform, $25 PT
-
UPDATE: H.C. Wainwright Starts Rezolute (RZLT) at Buy
-
Rezolute (RZLT) PT Lowered to $30 at Canaccord Genuity
-
Rezolute (RZLT) Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
-
Rezolute Inc. (RZLT) Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
-
Rezolute Inc. (RZLT) Begins Phase 1 Study of RZ402
-
Rezolute (RZLT) Announces FDA Clears its IND Application for RZ402
-
Rezolute (RZLT) PT Raised to $30 at JMP Securities
Back to RZLT Stock Lookup
